[go: up one dir, main page]

BR9917113A - Agente para tratar de distúrbio de função de células visuais compreendendo um inibidor de interleucina 2, seu método de tratamento e uso - Google Patents

Agente para tratar de distúrbio de função de células visuais compreendendo um inibidor de interleucina 2, seu método de tratamento e uso

Info

Publication number
BR9917113A
BR9917113A BR9917113-9A BR9917113A BR9917113A BR 9917113 A BR9917113 A BR 9917113A BR 9917113 A BR9917113 A BR 9917113A BR 9917113 A BR9917113 A BR 9917113A
Authority
BR
Brazil
Prior art keywords
interleukin
agent
inhibitor
treatment
cell function
Prior art date
Application number
BR9917113-9A
Other languages
English (en)
Inventor
Ryuji Ueno
Original Assignee
R Tech Ueno Ltd
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd, Fujisawa Pharmaceutical Co filed Critical R Tech Ueno Ltd
Publication of BR9917113A publication Critical patent/BR9917113A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"AGENTE PARA TRATAR DE DISTúRBIO DE FUNçãO DE CéLULAS VISUAIS COMPREENDENDO UM INIBIDOR DE INTERLEUCINA 2, SEU MéTODO DE TRATAMENTO E USO". A presente invenção provê um agente para o tratamento de distúrbio de função de células visuais contendo um inibidor de interleucina, tal como composto de macrolídeo, particularmente FK506.
BR9917113-9A 1998-12-24 1999-12-20 Agente para tratar de distúrbio de função de células visuais compreendendo um inibidor de interleucina 2, seu método de tratamento e uso BR9917113A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11393998P 1998-12-24 1998-12-24
PCT/JP1999/007161 WO2000038703A1 (en) 1998-12-24 1999-12-20 Agent for treating visual cell function disorder

Publications (1)

Publication Number Publication Date
BR9917113A true BR9917113A (pt) 2001-10-23

Family

ID=22352417

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9917113-9A BR9917113A (pt) 1998-12-24 1999-12-20 Agente para tratar de distúrbio de função de células visuais compreendendo um inibidor de interleucina 2, seu método de tratamento e uso

Country Status (13)

Country Link
EP (1) EP1140134A1 (pt)
JP (1) JP2002542150A (pt)
KR (1) KR20010099928A (pt)
CN (1) CN1224420C (pt)
AR (1) AR022017A1 (pt)
AU (1) AU781049B2 (pt)
BR (1) BR9917113A (pt)
CA (1) CA2356382A1 (pt)
MX (1) MXPA01006449A (pt)
NO (1) NO20013146L (pt)
NZ (1) NZ513111A (pt)
TW (1) TW546145B (pt)
WO (1) WO2000038703A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
AU2003209297A1 (en) 2002-01-18 2003-09-02 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
ES2494791T3 (es) 2002-09-18 2014-09-16 Trustees Of The University Of Pennsylvania Uso de rapamicina para el tratamiento o prevención de la degeneración macular asociada a la edad
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
GB2438544A (en) 2005-02-09 2007-11-28 Cooper Internat Corp Liquid formulations for treatment of diseases or conditions
WO2007019427A2 (en) * 2005-08-08 2007-02-15 Massachusetts Eye & Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
JP5528708B2 (ja) 2006-02-09 2014-06-25 参天製薬株式会社 安定な製剤ならびにそれらを調製および使用する方法
AU2007230964B2 (en) 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
EP3868407A4 (en) * 2018-10-15 2022-02-23 Osaka University MEDICATIONS FOR IMPROVING OR PREVENTING SYMPTOMS RELATED TO RETINA AND/OR PHOTORECEPTION AND METHODS OF SCREENING OF AN AGENT TO IMPROVE SYMPTOMS RELATED TO RETINA AND/OR PHOTORECEPTION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69124380T2 (de) * 1990-08-23 1997-08-14 Univ New York Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten
IL102414A (en) * 1991-07-25 1996-08-04 Univ Louisville Res Found Medicinal preparations for the treatment of ocular inflammation, containing rapamycin
US5922773A (en) * 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5597809A (en) * 1994-06-23 1997-01-28 Massachusetts Eye & Ear Infirmary Treatment of optic neuritis
US6380261B1 (en) * 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
CZ287497B6 (cs) * 1997-12-30 2000-12-13 Galena, A. S. Topické oční přípravky s imunosupresivními látkami
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders

Also Published As

Publication number Publication date
MXPA01006449A (es) 2002-04-24
NZ513111A (en) 2003-10-31
EP1140134A1 (en) 2001-10-10
CA2356382A1 (en) 2000-07-06
WO2000038703A1 (en) 2000-07-06
JP2002542150A (ja) 2002-12-10
CN1224420C (zh) 2005-10-26
AU1690600A (en) 2000-07-31
AU781049B2 (en) 2005-05-05
TW546145B (en) 2003-08-11
AR022017A1 (es) 2002-09-04
NO20013146D0 (no) 2001-06-22
KR20010099928A (ko) 2001-11-09
CN1352565A (zh) 2002-06-05
NO20013146L (no) 2001-08-20

Similar Documents

Publication Publication Date Title
BR0011225A (pt) Agente para tratar de olhos secos, seu método e uso
DK0918504T3 (da) Anvendelse af genistein som et forebyggende middel mod af ultraviolet stråling induceret hudfotobeskadigelse og cancer.
AU2713500A (en) Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
FI973492A0 (fi) NO-syntaasin estäjät
NZ517616A (en) Use of retigabin for treating neuropathic pain
NO976142D0 (no) Anvendelse av minst en NO syntase inhibitor i behandling av fölsom hud
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
DE69533697D1 (de) ANTISENSE OLIGONUKLEOTIDMODULATION DER raf GENEXPRESSION
IL138476A0 (en) Method for treating pharmaceutical compositions by special use of anti-oxidant
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
HK1047885A1 (zh) 肌氨酸或者肌氨酸化合物作為皮膚護理的用途
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
MX9306295A (es) Composiciones farmaceuticas para tratar sintomas de resfriado.
BR9507730A (pt) Uso de formulações em gel como composições de tratamento
AR004170A1 (es) Peptidos ciclicos semisinteticos, utiles como inhibidores de hongos y parasitos; procedimiento para prepararlos, formulaciones que los incluyeny metodo para tratar infecciones fungicas con aplicacion de dichas formulaciones
BR9917113A (pt) Agente para tratar de distúrbio de função de células visuais compreendendo um inibidor de interleucina 2, seu método de tratamento e uso
ES2104358T3 (es) Inhibidores sililados de acetilcolinesterasa.
BR9808221A (pt) Método de tratamento de tumor.
WO2001006990A3 (en) Use of etodolac to treat cancer
PT90085A (pt) Processo para a preparacao de composicoes farmaceuticas contendo um complexo organico de ouro para aplicacao topica
EE04711B1 (et) Antiseptiline kompositsioon, puidust või muust materjalist põhimiku töötlemismeetod, puidu või muu materjali kaitsmismeetod, oksatiasiini ühendi, pluss ühe või mitme kvaternaarse ammooniumiühendi ja triasooliühendi kasutamine
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
AR023194A1 (es) Agente antiincrustante que contiene thiacloprid
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: SUCAMPO AG (CH)

B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A. E 9A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DE RPI 1999 DE 28/04/2009.